Video

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

PALOMA-2 is a randomized double-blind phase III trial designed to confirm the results of PALOMA-1, which found that the addition of palbociclib (Ibrance) to letrozole (Femara) significantly improved progression-free survival compared with letrozole alone.

Preclinical data has suggested that patients with ER+ breast cancer would specifically benefit from a CDK 4/6 inhibitor such as palbociclib, Finn explains. The current data confirm the agent's consistent efficacy in several different subgroups of biomarkers.

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP